đź’¨ Abstract
Bolt Biotherapeutics Inc. reported a first-quarter loss of $11 million, or 29 cents per share, exceeding Wall Street's expectations of a 34 cents per share loss. The company's revenue was $1.2 million, surpassing analysts' forecast of $1 million. As of Monday's close, BOLT's shares were at 37 cents, down from $1.26 a year ago.
Courtesy: wtop.com
Summarized by Einstein Beta 🤖
Suggested
Walker, Svechnikov score late as Hurricanes push Capitals to brink of elimination in 5-2 win -
9 conclusiones del primer dĂa de testimonios en el juicio de Sean “Diddy” Combs -
The top photos of the day by AP’s photojournalists -
Asian shares gain after Wall Street’s rally, but hopes are tempered by trade war uncertainties -
Verdugo singles in White in bottom of 9th as Braves recover and beat slumping Nationals 4-3 -
Mercury fuels gold mining in Senegal. And it’s poisoning the people who use it -
Winn homers as the Cardinals beat the Phillies 3-2 for their 9th straight win -
Gleyber Torres homers and drives in 3 runs as Tigers rout Red Sox 14-2 -
Winning numbers drawn in Monday’s Delaware Play 5 Night -
Winning numbers drawn in Monday’s Maryland Pick 5 Evening -
Powered by MessengerX.io